A5029706624- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- Neuroendocrine Tumor Research Advances
- interferon and immune responses
- Sarcoma Diagnosis and Treatment
- Cancer Research and Treatments
- Lung Cancer Research Studies
- Cardiac tumors and thrombi
- Protein Degradation and Inhibitors
PharmaMar (Spain)
2024-2025
The plasticity of cancer cells facilitates their ability to adopt heterogeneous differentiation states, posing a significant challenge therapeutic interventions. Specific gene expression programs, driven in part by super-enhancers (SEs), underlie cell states. Here we successfully inhibit SE-driven transcription phenotypically distinct metastatic melanoma using next-generation synthetic ecteinascidins. Through functional genomic methodologies, demonstrate that these compounds the genes...
Abstract Lurbinectedin is a selective inhibitor of oncogenic transcription approved for the treatment adult patients with metastatic small cell lung cancer (SCLC) disease progression on or after platinum-based chemotherapy. Preclinical data provide evidence lurbinectedin exerting its actions in unique manner that involves inhibition, DNA damage, reshaping tumor microenvironment, and inducing anticancer immunity. Understanding mechanism action (MoA) has facilitated rational combination...
Trabectedin, approved for the treatment of soft tissue sarcoma (STS), interferes with cell division and genetic transcription processes. Due to its strong anti-tumor activity in only certain histotypes, several studies on trabectedin combinations are currently ongoing improve efficacy. In this study, we aimed investigate novel potential therapeutic strategies enhance effect using integrated silico, vitro, vivo approaches. For silico analysis, screened two public datasets, GSEA M5190 TCGA...